• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Catalent to float $400m debt offering

November 28, 2016 By Sarah Faulkner

Catalent to float $400m debt offeringCatalent (NYSE:CTLT) said today that it plans to fund its acquisition of soft-gel pharmaceutical capsule manufacturer Accucaps Industries Ltd with a $400 million debt offering.

The Somerset, N.J.-based company said the private placement offering of euro-dominated senior unsecured notes due in 2024 will also be used to repay some of the outstanding borrowings under its senior secured credit facilities, any accrued and unpaid interest, related fees and expenses.

Canada-based Accucaps has 2 facilities with high-potency prescription soft-gel development and manufacturing capabilities. Financial details of the acquisition have not been disclosed.

“Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments,” Catalent’s president of soft-gel technologies Aris Gennadios said in prepared remarks.

Earlier this month, Catalent posted 1st fiscal quarter profits of $4.6 million, or 4¢ per share, on sales of $442.2 million for the 3 months ended Sept. 30, for a bottom-line slide of -60.7% on sales growth of 4.5% compared with the same period last year. Adjusted to exclude 1-time items, earnings per share were 16¢, a penny ahead of consensus on The Street, where analysts were looking for sales of $430.2 million.

The company saw strong revenue growth in Q1 of 2017 and it’s acquisition of Pharmatek added spray drying technology to its portfolio of drug delivery technologies.

CTLT shares were trading at $24.75 in mid-morning activity today, down -0.7%.

Filed Under: Featured, Funding Roundup, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Catalent

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS